Marshall Wace, LLP Ascendis Pharma A/S Transaction History
Marshall Wace, LLP
- $74.4 Billion
- Q1 2025
A detailed history of Marshall Wace, LLP transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Marshall Wace, LLP holds 22,294 shares of ASND stock, worth $3.52 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,294
Previous 114,245
80.49%
Holding current value
$3.52 Million
Previous $15.7 Million
77.91%
% of portfolio
0.0%
Previous 0.02%
Shares
22 transactions
Others Institutions Holding ASND
# of Institutions
270Shares Held
61.9MCall Options Held
151KPut Options Held
226K-
Ra Capital Management, L.P. Boston, MA10.3MShares$1.63 Billion33.28% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$866 Million4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.22MShares$825 Million13.16% of portfolio
-
Janus Henderson Group PLC London, X04.49MShares$709 Million0.4% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$673 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $8.82B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...